Morningstar brands and products Company Portfolio ...

Utilizing its proprietary rabbit B Cell Select platform, the company aims to capitalize on the lucrative $81 billion anti-aging market by enhancing diagnostic and therapeutic approaches.

Background: Despite advances in graft versus host disease (GVHD) prevention, rabbit antithymocyte globulin (rATG) remains a guideline-based option (EBMT 2024), however dosing strategies are variable.

CAR T-cell therapy may offer better outcomes when diffuse large B-cell lymphoma (DLBCL) doesn’t respond to treatment or relapses.

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients ...

Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?, Expert ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

In a new study, researchers examined the efficacy and impact of CD19 CAR T cell therapy on B cells, specifically exploring its ability to deplete B cells in deep tissues and understand the therapeutic ...